The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax.
Eiken AP, Schmitz E, Drengler EM, Smith AL, Skupa SA, Mohan K, Rana S, Singh S, Mallareddy JR, Mathew G, Natarajan A, El-Gamal D.
Eiken AP, et al. Among authors: natarajan a.
Hemato. 2024 Sep;5(3):321-339. doi: 10.3390/hemato5030024. Epub 2024 Aug 27.
Hemato. 2024.
PMID: 39450301
Free PMC article.